Logo image of IOBT

IO BIOTECH INC (IOBT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IOBT - US4497781090 - Common Stock

0.7196 USD
-0.01 (-1.96%)
Last: 11/28/2025, 7:39:40 PM
0.708 USD
-0.01 (-1.61%)
After Hours: 11/28/2025, 7:39:40 PM
Fundamental Rating

1

Taking everything into account, IOBT scores 1 out of 10 in our fundamental rating. IOBT was compared to 533 industry peers in the Biotechnology industry. IOBT has a bad profitability rating. Also its financial health evaluation is rather negative. IOBT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IOBT had negative earnings in the past year.
IOBT had a negative operating cash flow in the past year.
IOBT had negative earnings in each of the past 5 years.
In the past 5 years IOBT always reported negative operating cash flow.
IOBT Yearly Net Income VS EBIT VS OCF VS FCFIOBT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

IOBT has a Return On Assets of -245.68%. This is amonst the worse of the industry: IOBT underperforms 92.13% of its industry peers.
With a Return On Equity value of -6531.78%, IOBT is not doing good in the industry: 83.15% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -245.68%
ROE -6531.78%
ROIC N/A
ROA(3y)-45.97%
ROA(5y)-105.42%
ROE(3y)-50.49%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IOBT Yearly ROA, ROE, ROICIOBT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 600 800

1.3 Margins

IOBT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IOBT Yearly Profit, Operating, Gross MarginsIOBT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for IOBT remains at a similar level compared to 1 year ago.
The number of shares outstanding for IOBT has been increased compared to 5 years ago.
There is no outstanding debt for IOBT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IOBT Yearly Shares OutstandingIOBT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
IOBT Yearly Total Debt VS Total AssetsIOBT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -19.92, we must say that IOBT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -19.92, IOBT is not doing good in the industry: 84.27% of the companies in the same industry are doing better.
IOBT has a Debt/Equity ratio of 4.22. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 4.22, IOBT is doing worse than 81.65% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 4.22
Debt/FCF N/A
Altman-Z -19.92
ROIC/WACCN/A
WACCN/A
IOBT Yearly LT Debt VS Equity VS FCFIOBT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 1.96 indicates that IOBT should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.96, IOBT is doing worse than 76.03% of the companies in the same industry.
IOBT has a Quick Ratio of 1.96. This is a normal value and indicates that IOBT is financially healthy and should not expect problems in meeting its short term obligations.
IOBT's Quick ratio of 1.96 is on the low side compared to the rest of the industry. IOBT is outperformed by 74.53% of its industry peers.
Industry RankSector Rank
Current Ratio 1.96
Quick Ratio 1.96
IOBT Yearly Current Assets VS Current LiabilitesIOBT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

IOBT shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 5.11%.
EPS 1Y (TTM)5.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

IOBT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.35% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.5%
EPS Next 2Y26.56%
EPS Next 3Y16.32%
EPS Next 5Y19.35%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IOBT Yearly Revenue VS EstimatesIOBT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
IOBT Yearly EPS VS EstimatesIOBT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IOBT. In the last year negative earnings were reported.
Also next year IOBT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IOBT Price Earnings VS Forward Price EarningsIOBT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IOBT Per share dataIOBT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as IOBT's earnings are expected to grow with 16.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.56%
EPS Next 3Y16.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IOBT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IO BIOTECH INC

NASDAQ:IOBT (11/28/2025, 7:39:40 PM)

After market: 0.708 -0.01 (-1.61%)

0.7196

-0.01 (-1.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-16 2026-03-16/amc
Inst Owners63.84%
Inst Owner Change-45.58%
Ins Owners0.34%
Ins Owner Change0.06%
Market Cap51.78M
Revenue(TTM)N/A
Net Income(TTM)-103.99M
Analysts76.67
Price Target2.51 (248.8%)
Short Float %4.21%
Short Ratio0.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.95%
Min EPS beat(2)3.61%
Max EPS beat(2)12.28%
EPS beat(4)2
Avg EPS beat(4)-6.88%
Min EPS beat(4)-22.76%
Max EPS beat(4)12.28%
EPS beat(8)5
Avg EPS beat(8)0.99%
EPS beat(12)7
Avg EPS beat(12)1.47%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-66.41%
PT rev (3m)-72.63%
EPS NQ rev (1m)0%
EPS NQ rev (3m)8.47%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 32.52
P/tB 32.52
EV/EBITDA N/A
EPS(TTM)-1.3
EYN/A
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0
BVpS0.02
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -245.68%
ROE -6531.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.97%
ROA(5y)-105.42%
ROE(3y)-50.49%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 4.22
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 29.88%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.96
Quick Ratio 1.96
Altman-Z -19.92
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%63.89%
EPS Next Y7.5%
EPS Next 2Y26.56%
EPS Next 3Y16.32%
EPS Next 5Y19.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-6.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.82%
EBIT Next 3Y-0.35%
EBIT Next 5Y6.16%
FCF growth 1Y-35.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.11%
OCF growth 3YN/A
OCF growth 5YN/A

IO BIOTECH INC / IOBT FAQ

What is the ChartMill fundamental rating of IO BIOTECH INC (IOBT) stock?

ChartMill assigns a fundamental rating of 1 / 10 to IOBT.


What is the valuation status for IOBT stock?

ChartMill assigns a valuation rating of 0 / 10 to IO BIOTECH INC (IOBT). This can be considered as Overvalued.


What is the profitability of IOBT stock?

IO BIOTECH INC (IOBT) has a profitability rating of 0 / 10.


Can you provide the financial health for IOBT stock?

The financial health rating of IO BIOTECH INC (IOBT) is 2 / 10.